Burosumab Biosimilar Monoclonal Antibody (FGF23) for Research

Cat No.: GMP-Bios-ab-086

Pre-Made Burosumab biosimilar, Whole mAb, Anti-FGF23 Antibody: Anti-ADHR/FGFN/HFTC2/HPDR2/HYPF/PHPTC therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Burosumab (INN, sold under the brand name Crysvita) is a human monoclonal antibody medication for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia.[ Burosumab was approved by the FDA for its intended purpose, in patients aged one year and older, in April 2018.[8] The FDA approval fell under both the breakthrough therapy and orphan drug designations. It was approved for use in the European Union in February 2018.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-086-1mg 1mg 243

Size: 1mg | 10mg | 100mg



Product Details

Products Name (INN Index) Pre-Made Burosumab biosimilar, Whole mAb, Anti-FGF23 Antibody: Anti-ADHR/FGFN/HFTC2/HPDR2/HYPF/PHPTC therapeutic antibody
INN Name Burosumab
TargetFGF23
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2016
Year Recommended2017
CompaniesKyowa Hakko Kirin;Ultragenyx Pharmaceutical
Conditions ApprovedX-linked dominant hypophosphataemic rickets;Osteomalacia
Conditions ActiveNevus
Conditions Discontinuedna
Development Techna



About target - FGF23

1. Protein Fibroblast growth factor 23

2. Gene FGF23

3. Organism Homo sapiens (Human)

Function
Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Upregulates EGR1 expression in the presence of KL (By similarity).
Acts directly on the parathyroid to decrease PTH secretion (By similarity).
Regulator of vitamin-D metabolism. Negatively regulates osteoblast differentiation and matrix mineralization.